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Abstract Previous research suggested that baseline
corrected distance visual acuity (CDVA) and maxi-
mum keratometry (Kmax) are the predictors for
effectiveness of corneal crosslinking (CXL) for ker-
atoconus. The aim of this study was to validate the
previously determined predictors in a new treatment
cohort. A prospective cohort of 112 eyes in 90
consecutive patients was used to validate the results
of 102 eyes in 79 patients from our previous prospec-
tive cohort. All patients were treated using epithelium-
off corneal CXL in a tertiary hospital setting. Primary
outcomes were changes in CDVA (LogMAR) and
Kmax between baseline and 1-year post-treatment.
Predictive factors for both outcomes were determined
using univariable and multivariable analyses. Lower
pretreatment CDVA was found to be the sole
independent factor predicting an improvement in
CDVA 1 year after CXL (b coefficient: -0.476,
P\ 0.01). Kmax flattening is more likely to take place
in eyes with preoperative central cones (b coefficient:
0.655, P\ 0.01). These results are consistent with our
initial research and indicate high reproducibility in the
new cohort. The previously postulated prediction
model for postoperative CDVA showed limited
predictive value in the validation cohort (R2 = 0.15).
The clinical implication of these results is that patients
with lower pretreatment visual acuity are more likely
to benefit from CXL (with respect to visual acuity),
and patients with more central cones will benefit more
in terms of cone flattening. Furthermore, those results
can be used to guide customization of the crosslinking
treatment.
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Introduction
Keratoconus is a progressive disease in which protru-
sion of the cornea causes visual impairment through
the formation of irregular astigmatism [1, 2]. The
typical age of onset for keratoconus is early adulthood,
and the disease is likely multifactorial in origin [3].
Genetic factors, environmental factors, positive fam-
ily history, atopic constitution, contact lens use, and
eye-rubbing have all been associated with keratoconus
[4–9]. To halt disease progression, corneal crosslink-
ing (CXL) has shown promising results in patients
with keratoconus [10–12]. However, continued dis-
ease progression and a further decrease in visual acuity
have been reported following CXL [13].
Many factors that might be related to the efficacy of
CXL have been studied previously. For example, age
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is associated with changes in visual acuity, as pediatric
patients show better improvement than older patients
in terms of corrected distance visual acuity (CDVA)
following CXL [14, 15]. A Snellen CDVA value
worse than 20/40 is also correlated with an improve-
ment in visual acuity following CXL [16, 17]. With
respect to flattening of maximum keratometry (Kmax)
following CXL, higher pretreatment Kmax (C54 D), a
more central cone, and central cornea thickness
C450 lm have all been reported as predictive factors
[16–21]. The majority of these associations were
established using univariable analyses, although
CDVA is known to be influenced by many interrelated
factors [22].
Predictors of CXL efficacy have previously been
studied by our group in a consecutive treatment
cohort; specifically, differences in CDVA and Kmax
1 year after CXL were assessed using a multivariable
model [23]. Interestingly, baseline CDVA was the
only independent factor for predicting change in
CDVA 1 year after CXL, and cone eccentricity was
the only independent factor associated with change in
Kmax following CXL. Moreover, a reliable model for
predicting post-CXL changes in CDVA was con-
structed (R2 = 0.45). In order to determine the
reliability and generalizability of this model, external
validation of these findings is essential.
Predictors are often not generalizable to patients
outside the study population. Our primary purpose was
to validate the reproducibility of previously deter-
mined predictors in a new treatment cohort. Only after
validation such results should be implemented in
clinical practice. Our secondary purpose was to
validate the previously published model for the
prediction of visual outcomes for individual patients
following CXL [23].
Methods
Dataset and study design
Our current cohort included patients who were treated
with epithelium-off CXL for progressive keratoconus
in our institution from January 1, 2012 to October 31,
2013. Here, we refer to this cohort as the validation
cohort. The study design, inclusion and exclusion
criteria, data collection, and surgical procedure were
adapted from the initial treatment cohort, which
included patients who were treated from January 1,
2010 through December 31, 2011 [23]. The inclusion
criteria included a prior Kmax progression of C1.0 D
within 6–12 months and thinnest corneal pachymetry
C400 lm. Patients with corneal scarring or infection,
pregnant patients, and lactating patients were
excluded. The following primary outcomes were
examined: (1) change in CDVA (logMAR CDVA)
between baseline and 1-year post-CXL, and (2)
change in Kmax between baseline and the 1-year
post-CXL. This study was approved by the Ethics
Review Board of the University Medical Center
Utrecht and was performed in accordance with local
laws, the European guidelines of Good Clinical
Practice, and the tenets of the Declaration of Helsinki.
Surgical procedure
After the corneal epithelium was removed, crosslink-
ing was performed in accordance with the Dresden
protocol, using UV radiation with a perpendicular
emission plane (370 nm at 3mW/cm2, UV-X, Peschke
Meditrade GmbH, Waldshut-Tiengen, Germany) as
described previously [22–25].
Data collection
Standard measurements were obtained at all follow-up
visits and included uncorrected distance visual acuity
(UDVA), CDVA, manifest refraction, Scheimpflug
corneal tomography (Pentacam HR type 70900, Ocu-
lus GmbH, Wetzlar, Germany), and slit lamp evalu-
ation. Parameters were measured prior to treatment
and at regular follow-up visits (1, 3, 6, 12, and
18 months of post-treatment). Patient-related factors,
including family history, atopic constitution, and
smoking history, were collected from the patient
charts and supplemented using standardized forms
completed by phone or e-mail in case they were not
noted in the patient charts. Family history was
considered positive if a first-degree or second-degree
relative had been diagnosed with keratoconus. Patients
with asthma, eczema, hay fever, or anti-allergy
medication were marked as positive for atopic consti-
tution. Patients who were current smokers or previous
smokers were marked as smokers, and the number of
pack-years was noted.
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Statistical analysis
Progression of keratoconus 1 year after CXL treatment
was defined as an increase in Kmax C1 D. The paired
Student’s t test was used to analyze the differences in
logMAR CDVA and Kmax between baseline and the
12-month follow-up visit. Five patients missed the
12-month follow-up visit, but they did attend the 6- and
18-month visits; for these patients, simple longitudinal
imputation was used to estimate their CDVA andKmax
values at 12 months [26].
In this validation cohort, univariable analysis was
performed in order to identify factors associated with
the primary outcome parameters (i.e., change in
CDVA and Kmax). All factors with P B 0.20 from
the univariable analysis were entered into a multivari-
able linear regression analysis to identify independent
predictive factors. This method is consistent with the
statistical method used to analyze the initial treatment
cohort. The analysis was performed using generalized
estimating equations, with correction for patients in
which both eyes were included in the study.
The prediction model, which was postulated based
on the initial treatment cohort, was sequentially
validated; pretreatment logMAR-transformed visual
acuity measurements of the validation cohort were
entered in the model. The predicted and observed
differences in logMAR CDVA values were compared
using linear regression and presented in a calibration
plot. Discrimination was summarized using R2 to
quantify the model’s performance. A new prediction
model based on the validation cohort was produced by
stepwise, backward removal of the least significant
factors derived from the multivariable analysis. To
validate the performance of the refined prediction
model, both calibration and discrimination were
tested. A calibration plot and additional R2 of the
observed and predicted values were obtained. Data




The validation cohort consisted of 112 eyes from 90
patients who were treated using CXL within the study
period. Ten eyes were lost to follow-up due to the
patients moving abroad (n = 2) or unknown reasons
(n = 8). These patients did not differ from the
remaining study sample with respect to their baseline
characteristics. Patient-related factors were unknown
in five patients. The baseline characteristics of the
initial and validation cohorts were similar, and are
summarized in Table 1.
At the 1-year post-CXL follow-up, progression had
halted in 94 of the 102 eyes that were still in the study
(92 %). The remaining eight eyes had progressed, with
a mean increase in Kmax of 3.9 D had progressed, with
a mean increase in Kmax of 3.9 D (range 1.40–9.40
D). Both visual acuity and Kmax had improved
significantly 1 year after CXL treatment. On average,
LogMAR CDVA improved from 0.30 to 0.21
(P\ 0.01), and Kmax decreased from 57.2 to 56.2
D (P\ 0.01).
Univariable analysis
The outcomes of our univariable analysis of the initial
treatment cohort and the current validation cohort are
summarized in Table 2. Both age (b coefficient: 0.006,
P = 0.04) and pretreatment CDVA (b coefficient:
-0.385, P\ 0.01) were associated with a change in
visual acuity. Of those two factors, only pretreatment
CDVA had been identified in the initial cohort.
None of the baseline factors was significantly
associated with Kmax outcome in the validation
cohort. Because pretreatment Kmax and cone eccen-
tricity demonstrated a trend toward association (b
coefficient: -0.046, P = 0.15 and b coefficient:
0.356, P = 0.17, respectively), they were entered in
the multivariable analysis. In the initial cohort, gender,
cone eccentricity, and corneal thickness were associ-
ated with Kmax outcome.
Multivariable analysis
Table 3 summarizes the results of the multivariable
analyses in both cohorts. In the validation cohort, age
(b coefficient: 0.007, P = 0.03) and pretreatment
CDVA (b coefficient:-0.476, P\ 0.01) were related
independently to a change in visual acuity at the 1-year
follow-up visit. Age was not identified as an indepen-
dent predictor in the initial cohort. With respect to
change in Kmax, cone eccentricity was confirmed as
an independent predictor of CXL outcome 1 year after
treatment (b coefficient: 0.655, P\ 0.01).
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Visual acuity and cone eccentricity were found to
be the sole repeatable and independent factors influ-
encing outcomes of keratoconus patients undergoing
CXL, demonstrating that patients with lower pretreat-
ment visual acuity are more likely to benefit from CXL
(in terms of visual acuity), and patients with more
central cones will benefit more in terms of cone
flattening.
Validation of prediction model
The following equation was used in the initial model to
predict the change in logMAR CDVA 1 year after
CXL [23]:
Difference in logMAR CDVA one year after CXL
¼ ð0:518  baseline logMAR CDVAÞ
þ 0:043:
This model showed robust predictive value in the
initial treatment cohort (R2 = 0.45), explaining 45 %
of the variation in CDVA. Validation of the model, in
which the validation cohort data are entered into the
existing prediction model, showed a mediocre fit
(R2 = 0.18), only explaining 18 % of the variation. It
was not possible to create a better prediction model
based on the validation dataset (R2 = 0.19). With
respect to change in Kmax 1 year after CXL, the
model showed limited predictive value in our initial
cohort (R2 = 0.15) [23]. Fitting a new model to the
validation data showed even worst predictive value
(R2 = 0.02).
Although postoperative CDVA was accurately
predicted based on pretreatment patient characteristics
in the original study, both visual acuity and maximum
keratometry were not predictable for individual
patients in this validation study.
Discussion
The aim of this study was to validate and test the
reproducibility of previously determined predictors of
CXL effectiveness in a new treatment cohort. This
validation cohort confirmed that pretreatment visual
acuity and cone eccentricity are the only two inde-
pendent factors for predicting change in postoperative
CDVA and Kmax, respectively. Repeatability of those
results is essential to apply these findings in practice
and to guide clinicians in their decision-making
process.
With respect to cone flattening and visual acuity
development, the clinical outcomes following CXL in
our cohorts are consistent with previous studies [11,
27, 28]. This again underscores the ability to compare
our results to other populations that were treated using
the Dresden protocol. Our initial and validation
cohorts are relatively large, and only a limited number
of cases were lost to follow-up. Interestingly, the
univariable analysis revealed major differences
Table 1 Baseline characteristics of the initial cohort of 102 eyes of 79 and validation cohort of 112 eyes of 90 keratoconus patients
Initial cohort (102 eyes in 79 patients) Validation cohort (112 eyes in 90 patients)
N SD/% Missing N SD/% Missing
Age (years), mean 23 ±8 0 23 ±8 0
Male, N 56 71 0 59 66 0
Right eye, N 43 42 0 60 54 0
Snellen CDVA, mean 20/32 ±20/64 0 20/33 ±20/68 1
logMAR CDVA, mean 0.3 ±0.4 0 0.3 ±0.3 1
Kmax (D), mean 59.5 ±8.8 0 57.4 ±7.7 0
Positive family history, N 8 10 2 7 8 8
Atopic constitution, N 34 43 2 55 61 6
Smokers, N 11 14 3 19 21 9
N Number of patients, SD standard deviation, CDVA corrected distance visual acuity, D diopters, logMAR logarithm of the minimal
angle of resolution, Kmax maximum keratometry
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between the initial and validation datasets, demon-
strating the variability among outcomes when inter-
factor correlation is not taken into account. Some
baseline measurements are interrelated and therefore
could potentially be (incorrectly) identified as predic-
tors when correlated to a true predictor. The predictive
factors derived from our multivariable analysis were
consistent between the study cohorts, which reflects
good reproducibility and stresses the importance of
performing a multivariable analysis. The clinical
implication of these results is that patients with lower
pretreatment visual acuity are more likely to benefit
from CXL (with respect to visual acuity), and patients
with more central cones will benefit more in terms of
Table 2 Univariable analysis of baseline characteristics related to treatment effect in keratoconus patients in the initial and vali-
dation cohorts 1 year after corneal crosslinking treatment
Difference in CDVA (logMAR)
Initial cohort Validation cohort
b coefficient§ 95 % CI P value b coefficient§ 95 % CI P value
Age (years) 0.001 -0.006 to 0.008 0.77 0.006 0.000 to 0.013 0.04
Male gender 0.041 -0.079 to 0.162 0.50 0.066 -0.040 to 0.172 0.22
Positive family history 0.003 -0.168 to 0.173 0.97 -0.061 -0.288 to 0.166 0.60
Atopic constitution 0.121 0.010 to 0.232 0.03 -0.008 -0.124 to 0.109 0.90
Smoking -0.047 -0.203 to 0.109 0.54 0.070 -0.065 to 0.205 0.31
Spherical equivalent (D) -0.002 -0.018 to 0.013 0.99 -0.003 -0.023 to 0.018 0.80
LogMAR UDVA pretreatment -0.180 -0.290 to -0.070 \0.01 -0.011 -0.119 to 0.096 0.83
LogMAR CDVA pretreatment -0.523 -0.641 to -0.405 \0.01 -0.385 -0.545 to -0.224 \0.01
Kmax pretreatment (D) -0.009 -0.016 to -0.003 \0.01 0.001 -0.006 to 0.008 0.68
Cone eccentricity (mm) 0.098 0.029 to 0.168 \0.01 0.026 -0.030 to 0.081 0.36
Central corneal thickness (lm) 0.001 0.000 to 0.003 0.04 0.000 -0.001 to 0.002 0.80
Difference in maximum keratometry (Kmax)
Initial cohort Validation cohort
b coefficient§ 95 % CI P value b coefficient§ 95 % CI P value
Age (years) 0.044 -0.130 to 0.102 0.13 -0.029 -0.087 to 0.029 0.33
Male gender 1.222 0.272 to 2.172 0.01 0.404 -0.572 to 1.381 0.41
Positive family history 0.693 -0.689 to 2.075 0.32 0.663 -1.441 to 2.766 0.53
Atopic constitution 0.246 -0.679 to 1.171 0.60 0.142 -0.928 to 1.213 0.79
Smoking -0.417 -1.688 to 0.854 0.52 0.674 -0.578 to 1.925 0.29
Spherical equivalent (D) 0.104 -0.022 to 0.230 0.12 -0.072 -0.259 to 0.115 0.45
LogMAR UDVA pretreatment -0.871 -1.791 to 0.049 0.06 0.162 -0.832 to 1.156 0.75
LogMAR CDVA pretreatment -0.771 -2.062 to 0.520 0.24 0.541 -1.117 to 2.198 0.52
Kmax pretreatment (D) -0.039 -0.091 to 0.014 0.14 -0.046 -0.109 to 0.017 0.15
Cone eccentricity (mm) 0.957 0.400 to 1.515 \0.01 0.356 -0.151 to 0.863 0.17
Central corneal thickness (lm) 0.011 0.001 to 0.023 0.04 0.003 -0.012 to 0.018 0.70
CDVA Corrected distance visual acuity, logMAR logarithm of minimal angle of resolution, CI confidence interval, D diopters, Kmax
maximum keratometry, UDVA uncorrected distance visual acuity
§ ß coefficient is the value referring to how a dependent variable will change, per unit increase in the predictor variable
 P\ 0.05 indicates significance and this factor is included in multivariable analysis
 P values B 0.20 were also included in the multivariable analysis
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cone flattening. This is consistent with other studies in
which patients with a pretreatment CDVA of 20/40 or
worse had significant visual improvement [16, 17].
Therefore, it might be advisable to explain to patients
with low pretreatment CDCVA that improvement
might be expected, while on the other hand, this is not
likely for patients with pre-existent high CDVA.
Our finding that Kmax is more likely to flatten in
eyes with a more central cone is in concordance with
results from Greenstein et al. [20]. This latter finding
might be due to exposure to UV light perpendicular to
the center of the cornea during CXL. The peripheral
cornea receives light rays that are less potent due to
their oblique incidence. The UV light source used in
this study is in accordance with this principle.
Furthermore, it is known that CXL and aberrations
interact and it could be that aberrations in the vicinity
of a peripheral cone alter the angle of incidence of the
light rays on the corneal surface even further, causing
deflection and thereby resulting in less UV light
penetration in the cornea and lesser treatment results
[29]. Therefore, a more central cone is likely to be
treated more effectively, resulting in more flattening
of the cone. Focusing the UV light on the cone instead
of the center of the cornea could be considered for
treatment customization in patients with more periph-
eral cones.
Our initial study cohort did not identify age as a
predictive factor for either treatment outcomes. How-
ever, in the validation dataset, younger patients
benefitted significantly more with respect to visual
acuity. Soeters et al. also identified age as a prognostic
factor; interestingly, they also found that their younger
patients had more centrally located cones [14]. Le´oni-
Mesplie´ et al. reported that disease progression in
pediatric patients is more aggressive than in adults,
Table 3 Multivariable analysis of predictors of treatment effect in keratoconus patients in the initial and validation cohort 1 year
after corneal crosslinking treatment
Difference in CDVA (logMAR)
Initial cohort Validation cohort
b coefficient§ 95 % CI P value b coefficient§ 95 % CI P value
Age (years) -0.002 -0.008 to 0.004 0.50 0.007 0.001 to 0.013 0.03
Atopic constitution -0.048 -0.129 to 0.023 0.18
logMAR UDVA 0.069 -0.083 to 0.221 0.37
logMAR CDVA -0.628 -0.997 to -0.258 \0.01 -0.476 -0.680 to -0.271 \0.01
Kmax (D) 0.005 -0.001 to 0.011 0.13
Cone eccentricity (mm) 0.026 -0.044 to 0.096 0.46
Central corneal thickness (lm) 0.000 -0.001 to 0.001 0.53
Difference in maximum keratometry (Kmax)
Initial cohort Validation cohort
b coefficient§ 95 % CI P value b coefficient§ 95 % CI P value
Male gender -0.823 -1.923 to 0.277 0.14
Spherical equivalent (D) 0.103 -0.045 to 0.251 0.17
logMAR UDVA -0.017 -1.105 to 1.071 0.98
Kmax (D) -0.009 -0.068 to 0.050 0.77 0.012 -0.059 to 0.083 0.74
Cone eccentricity (mm) 0.709 0.117 to 1.301 0.02 0.655 0.210 to 1.101 \0.01
Central corneal thickness (lm) 0.001 -0.010 to 0.012 0.84
CDVA Corrected distance visual acuity, logMAR logarithm of minimal angle of resolution, CI confidence interval, D diopter, Kmax
maximum keratometry, UDVA uncorrected distance visual acuity
§ ß coefficient is a value referring to how a dependent variable will change, per unit increase in the predictor variable
 P\ 0.05 indicates significant values
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suggesting that CXL treatment is more effective at
preventing deterioration in pediatric patients [30].
Consistent with our initial study, a variety of factors
associated with keratoconus were not identified as
independent contributors to the effectiveness of CXL
treatment. These factors include gender, family his-
tory, atopic constitution, smoking history, spherical
equivalent, logMAR UDVA, Kmax, and central
corneal thickness; none of these factors were predic-
tive in terms of changes in visual acuity or Kmax
1 year after CXL. However, using univariable analy-
ses, other studies found that pretreatment corneal
thicknessB450 lm and Kmax C54 D were predictors
of a decrease in Kmax [16, 17, 19]. Although we also
found a relationship between corneal thickness and
Kmax flattening in our initial univariable analysis, this
relationship did not hold when examined in a multi-
variable analysis. This finding was not replicated in
the univariable analysis of our validation cohort.
Previously, Greenstein et al. used a multivariable
approach and found that patients with higher ker-
atometry readings showed more improvement in
response to CXL [16]. However, this finding is not
supported by our data. Additional analysis using a
dichotomous cut-off of 54 D was not associated with
either outcome parameter (data not shown). One
explanation for this difference in findings could be the
difference in sample size and the fact that Greenstein
et al. examined a heterogeneous study cohort that
included both patients with keratoconus and patients
with post-LASIK ectasia.
Creating a model for the prediction of individual
Kmax after CXL was ultimately cumbersome and
yielded little additional clinical value. Moreover, our
initial reliable model for the prediction of CDVA
could not be confirmed in this validation study, which
is an additional argument why validation studies are
extremely important. The inability to validate this
prediction model can be due to either overfitting of the
original model or to large individual variation in the
reaction to CXL treatment. Both options leading to the
conclusion that the formerly proposed prediction
model for individual visual outcomes after CXL
treatment should not be applied for patient counseling.
In conclusion, the clinical implication of these
results is that patients with lower pretreatment visual
acuity are more likely to benefit from CXL (with
respect to visual acuity), and patients with more
central cones will benefit more in terms of cone
flattening. Repeatability of those predictors supports
applicability for the decision-making process of
clinicians. Furthermore, those results can be used to
guide customization of the crosslinking treatment.
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